GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (OTCPK:IPSEF) » Definitions » Net Intangibles Purchase And Sale

Ipsen (IPSEF) Net Intangibles Purchase And Sale : $-466 Mil (TTM As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Ipsen Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Ipsen's net Intangibles purchase and sale for the six months ended in Dec. 2024 was $-134 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Dec. 2024 was $-466 Mil.

Ipsen Net Intangibles Purchase And Sale Historical Data

The historical data trend for Ipsen's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen Net Intangibles Purchase And Sale Chart

Ipsen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only Premium Member Only -53.89 -371.98 -165.57 -78.74 -456.75

Ipsen Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -102.12 -34.35 -44.17 -331.65 -134.14

Ipsen Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-466 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipsen Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of Ipsen's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

Ipsen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (OTCPK:IPSEF) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
XPAR:VETO XPAR:BOI XPAR:EAPI XPAR:AB XPAR:MLCOT XPAR:ALRPD ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 SZSE:000538 TSE:4507
Traded in Other Exchanges
IPSEY:USA IPNp:UK 0MH6:UK IPN:France I7G0:Germany I7G:Germany I7G:Germany IPN:Austria
Address
70 rue Balard, Paris, FRA, 75015
Website
https://www.ipsen.com
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.